Experimental cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT07454642
Summary
This is the first human study of an experimental cancer drug called AVA6103. It's being tested in adults with advanced solid tumors that have spread or can't be surgically removed, including pancreatic, lung, gastric, and cervical cancers. The trial aims to find the safest dose and see if the drug shows early signs of helping control these cancers in people who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.